Finder is committed to editorial independence. While we receive compensation when you click links to partners, they do not influence our content.

How to buy Outlook Therapeutics stock in Canada | $2.68

Own Outlook Therapeutics shares in just a few minutes.

Outlook Therapeutics, Inc
-$0.06 (-2.42%)

Outlook Therapeutics is a biotechnology business based in the US. Outlook Therapeutics stocks (OTLK.US) are listed on the NASDAQ and all prices are listed in US Dollars. Its last market close was $2.5 – an increase of 8.06% over the previous week. Outlook Therapeutics employs 8 staff and has a trailing 12-month revenue of around $5.9 million.

How to buy Outlook Therapeutics stock in Canada

  1. Choose a platform. If you're a beginner, our stock trading table below can help you choose.
  2. Open your account. You'll need your ID, bank details and national insurance number.
  3. Confirm your payment details. You'll need to fund your account with a bank transfer, debit card or credit card.
  4. Search the platform for stock code: OTLK in this case.
  5. Research Outlook Therapeutics stocks. The platform should provide the latest information available.
  6. Buy your Outlook Therapeutics stocks. It's that simple.

How has Coronavirus impacted Outlook Therapeutics's stock price?

Since the stock market crash in March caused by coronavirus, Outlook Therapeutics's stock price has had significant positive movement.

Its last market close was $2.68, which is 64.43% up on its pre-crash value of $0.9534 and 437.07% up on the lowest point reached during the March crash when the stocks fell as low as $0.499.

If you had bought $1,000 worth of Outlook Therapeutics stocks at the start of February 2020, those stocks would have been worth $582.38 at the bottom of the March crash, and if you held on to them, then as of the last market close they'd be worth $2,865.40.

Outlook Therapeutics stock price

Use our graph to track the performance of OTLK stocks over time.

Outlook Therapeutics stocks at a glance

Information last updated 2021-07-23.
Latest market close$2.68
52-week range$0.58 - $4.26
50-day moving average $2.4935
200-day moving average $2.153
Wall St. target price$5.33
Dividend yield N/A (0%)
Earnings per share (TTM) $-2.886

Compare online stock trading platforms

Note: The dollar amounts in the table below are in Canadian dollars.

Name Product Available asset types Stock Fee Option Fee Account Fee ETF Transaction Cost Feature Table description
Wealthsimple Trade
Stocks, ETFs
Get a $50 bonus when you open a Wealthsimple Trade account and deposit and trade at least $100.
Pay no commissions when you trade Canadian stocks and ETFs with Wealthsimple Trade.
Scotia iTRADE
Bonds, Options, Mutual Funds, ETFs, GICs, International Equities
$9.99 + $1.25 contract ($4.99 + $1.25 contract if completed 150 trades or more a quarter)
$9.99 ($4.99 if completed 150 trades or more a quarter)
Pay no annual account fees.
Buy, sell and trade ETFs, Equities, Options and more with competitive commissions.
CIBC Investor's Edge
Stocks, Bonds, Options, Mutual Funds, ETFs
$4.95 - $6.95
$4.95 - $6.95 (+$1.25 per contract)
$0 if conditions met, otherwise $100/year
$4.95 - $6.95 is applicable for online stock, ETF and option trades only. Pay $4.95 when you qualify as an Active Trader (trade 150+ times per quarter).
An intuitive and easy-to-use platform with access to a variety of tools that help you make smart decisions and trade with confidence.
Interactive Brokers
Stocks, Bonds, Options, ETFs, Currencies, Futures
Min. $1.00, Max. 0.5% of trade value
$1.50 min. per order
$0 (if monthly commissions are greater than or equal to US$10.00)
Min. $1.00, Max. 0.5% of trade value
Extensive trading capabilities and global investment tracking.
Access market data 24 hours a day, six days a week and invest in global stocks, options, futures, currencies, bonds and funds from one single account.
Stocks, Bonds, Options, Mutual Funds, ETFs, GICs, International Equities, Precious Metals
$9.95 + $1 per contract
Get $50 in free trades when you fund your account with a minimum of $1,000.
Opt for self-directed investing and save on fees or get a pre-built portfolio and take some of the guesswork out.
Qtrade Direct Investing
Stocks, Bonds, Options, Mutual Funds, ETFs, GICs
$6.95 - $8.75
$6.95 - $8.75 + $1.25 per contract
$0 if conditions met, otherwise $25/quarter
$0 - $8.75
Trade 100 select ETFs free of charge.
Qtrade Direct Investing offers low trading commissions and an easy-to-use platform with access to powerful tools and a wide selection of investment options. Trade 100 ETFs free of charge and thousands more for $8.75 or lower.

Compare up to 4 providers

Online stock trading

Is it a good time to buy Outlook Therapeutics stock?

The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.

Outlook Therapeutics price performance over time

Historical closes compared with the last close of $2.68

1 month (2021-06-25) 10.74%
3 months (2021-04-26) 18.06%

Outlook Therapeutics financials

Revenue TTM USD$5.9 million
Gross profit TTM USD$-26,341,998
Return on assets TTM -104.25%
Return on equity TTM -64034.97%
Profit margin 0%
Book value $0.119
Market capitalisation USD$430.5 million

TTM: trailing 12 months

How to short and sell Outlook Therapeutics stocks

  1. Create a CFD or spread betting account.
  2. Search for the stock code. E.g. "OTLK.US"
  3. Choose your position size.
  4. Select "sell" rather than "buy".
  5. Confirm your position and keep tabs on it. You may wish to set limits on your position.

There are currently 4.2 million Outlook Therapeutics stocks held short by investors – that's known as Outlook Therapeutics's "short interest". This figure is 214.1% up from 1.3 million last month.

There are a few different ways that this level of interest in shorting Outlook Therapeutics stocks can be evaluated.

Outlook Therapeutics's "short interest ratio" (SIR)

Outlook Therapeutics's "short interest ratio" (SIR) is the quantity of Outlook Therapeutics stocks currently shorted divided by the average quantity of Outlook Therapeutics stocks traded daily (recently around 1.3 million). Outlook Therapeutics's SIR currently stands at 3.37. In other words for every 100,000 Outlook Therapeutics stocks traded daily on the market, roughly 3370 stocks are currently held short.

However Outlook Therapeutics's short interest can also be evaluated against the total number of Outlook Therapeutics stocks, or, against the total number of tradable Outlook Therapeutics stocks (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case Outlook Therapeutics's short interest could be expressed as 0.02% of the outstanding stocks (for every 100,000 Outlook Therapeutics stocks in existence, roughly 20 stocks are currently held short) or 0.0475% of the tradable stocks (for every 100,000 tradable Outlook Therapeutics stocks, roughly 48 stocks are currently held short).

Such a low SIR usually points to an optimistic outlook for the stock price, with fewer people currently willing to bet against Outlook Therapeutics.

Find out more about how you can short Outlook Therapeutics stock.

Outlook Therapeutics stock dividends

We're not expecting Outlook Therapeutics to pay a dividend over the next 12 months. However, you can browse other dividend-paying stocks in our guide.

Have Outlook Therapeutics stocks ever split?

Outlook Therapeutics stocks were split on a 1:8 basis on 18 March 2019. So if you had owned 8 shares the day before before the split, the next day you'd have owned 1 share. This wouldn't directly have changed the overall worth of your Outlook Therapeutics stocks – just the quantity. However, indirectly, the new 700% higher stock price could have impacted the market appetite for Outlook Therapeutics stocks which in turn could have impacted Outlook Therapeutics's stock price.

Outlook Therapeutics stock price volatility

Over the last 12 months, Outlook Therapeutics's stocks have ranged in value from as little as $0.58 up to $4.26. A popular way to gauge a stock's volatility is its "beta".

OTLK.US volatility(beta: 0.68)Avg. volatility(beta: 1.00)LowHigh

Beta is a measure of a stocks volatility in relation to the market. The market (NASDAQ average) beta is 1, while Outlook Therapeutics's is 0.6817. This would suggest that Outlook Therapeutics's stocks are less volatile than average (for this exchange).

Outlook Therapeutics overview

Outlook Therapeutics, Inc., a late clinical-stage biopharmaceutical company, focuses on developing and commercializing monoclonal antibodies for various ophthalmic indications. Its lead product candidate is ONS-5010, a proprietary ophthalmic formulation of bevacizumab product candidate that is in Phase-III clinical trial for the treatment of wet age related macular degeneration and other retina diseases. Outlook Therapeutics, Inc. has collaboration and license agreements with IPCA Laboratories Limited; Laboratorios Liomont, S.A. de C.V.; BioLexis Pte. Ltd.; and Zhejiang Huahai Pharmaceutical Co., Ltd. The company was formerly known as Oncobiologics, Inc. and changed its name to Outlook Therapeutics, Inc. in November 2018. Outlook Therapeutics, Inc. was incorporated in 2010 and is headquartered in Cranbury, New Jersey.

Stocks similar to Outlook Therapeutics

Frequently asked questions

Disclaimer: This information should not be interpreted as an endorsement of futures, stocks, ETFs, CFDs, options or any specific provider, service or offering. It should not be relied upon as investment advice or construed as providing recommendations of any kind. Futures, stocks, ETFs and options trading involves substantial risk of loss and therefore are not appropriate for all investors. Trading CFDs and forex on leverage comes with a higher risk of losing money rapidly. Past performance is not an indication of future results. Consider your own circumstances, and obtain your own advice, before making any trades.

More on investing

More guides on Finder

Ask an Expert

You must be logged in to post a comment.

Go to site